SYNERGY: Custirsen in Poor-Prognosis mCRPC

May 29-June 2, 2015; Chicago, Illinois
A retrospective exploratory analysis of the phase III SYNERGY trial shows that adding custirsen to docetaxel/prednisone selectively improves survival in treatment-naive patients with mCRPC and a poor prognosis.
Format: Microsoft PowerPoint (.ppt)
File Size: 452 KB
Released: June 5, 2015


Educational grant provided by:
Bayer Healthcare Pharmaceuticals, Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Novartis Pharmaceuticals Corporation

Related Content

Expert insight by Dr Karim Fizazi on incorporating AR-targeted therapy into the management of nonmetastatic CRPC from Clinical Care Options (CCO)

Karim Fizazi, MD, PhD Released: June 30, 2020

ARV-110 shows promising activity in patients with resistance to second-generation AR treatments, from ASCO 2020 as reported by Clinical Care Options (CCO)

Released: June 8, 2020

Results from ARAMIS trial with darolutamide plus ADT vs placebo plus ADT in patients with nonmetastatic CRPC, from ASCO 2020 as reported by Clinical Care Options (CCO)

Released: June 4, 2020

Get a preview of key studies at ASCO 2020 from experts in both solid tumors and hematologic malignancies from Clinical Care Options

Ian W. Flinn, MD, PhD Axel Grothey Headshot Axel Grothey, MD Sara Hurvitz, MD, FACP Shaji Kumar, MD Stephen V. Liu, MD Bradley J. Monk, MD, FACS, FACOG Daniel P. Petrylak, MD Zofia Piotrowska, MD, MHS Elizabeth R. Plimack, MD, MS Farhad Ravandi, MD Manish A. Shah, MD Released: May 27, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?